Announced Tue, 4 Aug · 11:59 IST
Q1 FY27 Earnings Call: Revenue Up 8.2%, Margins Improve, Debt Down
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedCfo Debt Reduction RoadmapMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹222.01
prior close
₹223.45
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.2+1.1+1.5+0.2-0.5-0.2-1.2-2.3+0.4————
Up moveDown movePending
AI summary
Indoco Remedies Q1 FY27: consolidated revenue grew 8.2% YoY to INR4,662 million, standalone up 5.8% to INR4,081 million. Standalone EBITDA margin expanded to 10.3% from 3.8% YoY at INR422 million. US business surged 62.2% to INR459 million, API grew 42.4% to INR521 million. International formulations at INR1,451 million. Debt reduced to INR930 crores, with plans to repay INR260 crores over 18 months. Management targets double-digit EBITDA margins. USFDA sterile plant audit pending 6 plus months.
Likely market impact
Strong margin gains and US/API growth support outlook, but pending USFDA audit and emerging markets softness are key risks.